期刊文献+

荧光PCR探针熔解曲线法检测结核分枝杆菌耐利福平突变研究 被引量:9

Evaluation of the mutations detection of rpoB gene in Mycobacterium tuberculosis clinical isolates by probe melting analysis based real-time PCR
原文传递
导出
摘要 目的对荧光PCR熔解曲线法检测结核分枝杆菌耐利福平突变方法进行临床研究,评价检测能力及在国境口岸的应用价值。方法应用荧光PCR熔解曲线法检测结核病人临床分离结核分枝杆菌,以传统药物敏感性试验为标准,获得该方法的灵敏性、特异性。结果对347例结核病人临床分离培养样本,传统药物敏感性试验检出271例利福平敏感标本,76例利福平耐药标本。荧光PCR熔解曲线法检出269例利福平敏感标本,78例利福平耐药标本,灵敏性为93.42%,特异性为97.42%,符合率为96.54%。结论荧光PCR熔解曲线法检测速度快速、灵敏度高、特异性强,可用于结核分枝杆菌利福平耐药突变的快速检测,适于国境口岸对耐多药结核病的快速筛查。 Objective To evaluate the analysis abilities and valuation of the melting analysis based real-time PCR for detecting the mutations of ropB gene in mycobacterium tuberculosis from clinical samples at frontier port.Methods The probe melting analysis assay was adopted for the sensitivity and specificity in detecting the isolates from clinical samples against the standard of drug susceptibility testing(DST).Results A total of 347 mycobacterium tuberculosis isolates were detected by two methods,in which,271 rifampin sensitivity isolates and 76 rifampin resistant isolates were gained by DST.Meanwhile,269 rifampin sensitivity isolates and 78 rifampin resistant isolates were gained by the probe melting analysis assay,the sensitivity and specificity of melting analysis assay was 93.42% and 97.42%,respectively.The concordance of the two methods was 96.54%.Conclusion The probe melting analysis assay own the characteristics of short-time,higher sensitivity and specificity for detecting rifampin resistance in tuberculosis using clinical sample and is available to use for rapid screening multidrug drug resistant tuberculosis at frontier ports.
出处 《中国国境卫生检疫杂志》 CAS 2011年第6期451-454,共4页 Chinese Journal of Frontier Health and Quarantine
关键词 结核分枝杆菌 熔解曲线法 利福平 检测 Mycobacterium tuberculosis Melting analysis assay Rifampin Detect
  • 相关文献

参考文献15

  • 1Alan R Hinman, James M Hughes, Dixie E Snider. Meeting the challenge of mnltidrug-resistant tuberculosis: summary of a confer- ence. MMWR,1992,41(RR- 11):51-57.
  • 2American Thoracic Society, CDC, Infectious Disease Society of America. Treament of tuberculosis. MMWR,2003,52(RR-11):1-77.
  • 3Luna,J.C.A tuberculosis guide for specialist physicians.lnternation- al Union Against Tuberculosis and Lung Disease[M].Paris:2004.
  • 4WHO.Global tuberculosis report control (surveillance, planning, fi- nancing). Gevena: WHO/HTMfrB,2008.
  • 5中华人民共和国卫生部.全国结核病耐药基线调查报告(2007-2008年)[R].人民卫生出版社,2010.
  • 6Stefan HE Kaufmann,Eric Rubin.Handbook of tuberculosis:Molec- ular biology and biochemistry.Germany[M].WILEY-Verlag GmbH & Co.KGaA,Weinheim,2008.
  • 7Telenti A, Imboden P, Marehesi F, et al Detection of rifampicin resistance mutations in Mycobacterium tuberculosis[J]. Lance, 1993,341 (8846) : 664-665.
  • 8Espinal MA, Dye C, Raviglione M. Rational 'DOTS plus' for the control of MDR-rib[J]. Int J Tuberc Lung Dis, 1999,3(7) : 561-563.
  • 9牛建军,张轶,温慧欣,刘歆,胡思玉,李庆阁.应用探针熔解分析法检测结核分枝杆菌rpoB基因突变[J].中华预防医学杂志,2011,45(3):225-229. 被引量:3
  • 10Quan S, Venter H, Dabbs ER. Ribosylative inactivation of ri- fampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic[J]. Antimicrob Agents Che- mother,1997,41(10):2456-2460.

二级参考文献29

共引文献23

同被引文献96

引证文献9

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部